BioSpace News Archive

Prevail Therapeutics Inc., a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in the following virtual investor conferences in November and December:

– ReDUX4 trial progressing ; f ull data with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) expected in 2Q 2021 – – On track to begin dosing Phase 1 trial with FTX-6058 for sickle cell disease before YE 2020 – – Cash runway into 2Q 2022 – – Key a ppointment s to management team – – Conference call scheduled for 8:00 a.m. ET today – CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC),

AlloVir, a late clinical-stage cell therapy company, reported financial results for the third quarter ended September 30, 2020.

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2020, and provided an update on the Company’s recent corporate developments. “This quarter, we continued to make important progress in the advanceme

Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, will hold an investor call to introduce its multi-year financial targets for growth and improved profitability and will host a question-and-answer session.

Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced financial results for the third quarter 2020.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock.

Topline Data for HST-001 Phase 1b/2a Trial for Androgenic Alopecia in Men on Track for 4Q20 Received $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee Appointed Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations Received IND Approval from FDA to Initiate a Phase 1 Study

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that President, chief executive officer and director, Todd Smith will present at and participate in investor meetings at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020. The presentation will take place at 11:20 am ET A live audio webcast of the presentation can be accessed through the Investors secti

Third quarter GAAP net sales of $1.13 billion, an increase of 11% year-over-year; non-GAAP organic net sales increased 12% year-over-year